Kana Mizuno, PhD

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. Marsh, R; Khoury, R; Mizuno, K; Hosawi, A; Cottrell, C; Nguyen, E; Landon, B; Chandra, S; Jordan, M; Kumar, A; Bleesing, J; Davies, S; Moore, C; Mehta, P. 2025; 1.

Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Mehta, PA; Nelson, A; Loveless, S; Lane, A; Fukuda, T; Teusink-Cross, A; Elder, D; Lagory, D; Miller, E; Cancelas, JA; Edwards, S; Chihanga, T; Wells, SI; Davies, SM. Blood Advances. 2025; 9:1927-1939.

Unraveling the Challenges of Non-Responders to the Eculizumab Treatment with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA). Mizuno, K; Teusink-Cross, A; Sabulski, DA; Davies, SM; Jodele, S. Transplantation and Cellular Therapy. 2025; 31:s542-s543.

A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA. Jodele, S; Dandoy, CE; Aguayo-Hiraldo, P; Lane, A; Teusink-Cross, A; Sabulski, A; Mizuno, K; Laskin, BL; Freedman, J; Davies, SM. Blood. 2024; 143:1112-1123.

Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies. Jodele, S; Mizuno, K; Sabulski, A; Vinks, AA. Clinical Pharmacology and Therapeutics. 2023; 114:511-514.

Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy. Mizuno, K; Capparelli, EV; Fukuda, T; Dong, M; Adamson, PC; Blumer, JL; Cnaan, A; Clark, PO; Reed, MD; Shinnar, S; Vinks, AA; Glauser, TA. Clinical Pharmacology and Therapeutics. 2023; 114:459-469.

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. Yi, JS; Perla, S; Huang, Y; Mizuno, K; Giordano, FJ; Vinks, AA; Bennett, AM. Cardiovascular Drugs and Therapy. 2022; 36:589-604.

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, AA; Jodele, S. Blood Advances. 2022; 6:1454-1463.

187 Eculizumab Precision Dosing Algorithm for TA-TMA in Children and Young Adults Undergoing Stem Cell Transplant. Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, A; Jodele, S. Transplantation and Cellular Therapy. 2022; 28:s154-s155.

Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. Chandra, S; Mizuno, K; Zhao, J; Davies, SM; Marsh, RA; Fukuda, T; Setchell, KD R; Vinks, AA; Mehta, PA. British Journal of Clinical Pharmacology. 2022; 88:115-127.